Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2020-02-19 Capital/Financing Update
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia announces intention of a directed share issue
Capital/Financing Update Classification · 100% confidence The document is a press release from Cantargia AB announcing an intention to conduct a directed share issue (a capital raise). It details the purpose of the funds, the engagement of bookrunners, and the regulatory context of the offering. This falls under the category of capital/financing updates as it describes a specific corporate action to raise capital through the issuance of new shares.
2020-02-19 English
Cantargia offentliggör avsikt att genomföra riktad nyemission av aktier
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Cantargia AB announcing its intention to conduct a directed share issue (a private placement). It details the purpose of the capital raise, the involvement of financial advisors (Joint Bookrunners), and the regulatory framework for the offering. Since this document announces a new share issuance and capital change, it falls under the 'Share Issue/Capital Change' category.
2020-02-19 Swedish
Cantargia avancerar utvecklingen av CAN04 genom framgångsrik uppskalning av produktionen
Regulatory Filings Classification · 99% confidence The document is a press release dated February 14, 2020, announcing a significant operational milestone for Cantargia AB: the successful first GMP production scale-up of their drug candidate CAN04 to 2,000 liters. It discusses progress in clinical trials (Phase IIa), manufacturing agreements (Patheon), and future regulatory documentation needs. This type of announcement, focusing on operational progress, clinical updates, and manufacturing achievements, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about operational progress rather than a comprehensive financial report (10-K, IR) or a formal notice of a report being published (RPA), and it contains key highlights about the business/pipeline, ER is a strong candidate. However, given the focus is purely on operational/pipeline progress and not quarterly financial figures, and it is explicitly stated to be published under the EU Market Abuse Regulation, it fits well as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period. Since it is a standalone operational update, RNS is the most appropriate general regulatory category, although ER often includes such operational highlights. Given the context of a biotech company announcing a production milestone, RNS (Regulatory Filings) serves as the best fit for a non-standard, mandatory disclosure that isn't a full financial report or a specific management discussion.
2020-02-14 Swedish
Cantargia advances development of CAN04 through successful production scale up
Regulatory Filings Classification · 99% confidence The document is a press release dated February 14, 2020, announcing a successful production scale-up milestone for the antibody project CAN04. It details operational progress (GMP batch in 2,000-litre scale) relevant to future clinical trials and commercial manufacturing. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement concerning operational/development progress, which often falls under general investor relations or regulatory disclosure. Since it is a specific operational update that doesn't fit the definitions for DIV, CAP, MANG, DIRS, or LTR, and it is not a presentation (IP) or a transcript (CT), the most appropriate general category for a significant, non-financial, non-meeting-related corporate announcement that must be made public (as indicated by the EU Market Abuse Regulation disclosure) is the general Regulatory Filings category (RNS), as it serves as a broad disclosure mechanism for material, non-standardized news.
2020-02-14 English
Cantargia väljer CAN10 som utvecklingsprojekt inom systemisk skleros och myokardit
Regulatory Filings Classification · 99% confidence The document is a 'Pressmeddelande' (Press Release) dated December 5, 2019, from Cantargia AB. It announces the advancement of a research project (CAN10) focusing on systemic sclerosis and myocarditis, detailing the scientific rationale, development plan, and timeline for clinical trials. The text concludes with a statement that this information is required to be made public under the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning') and provides contact information. This structure—a formal announcement of a significant corporate/research development, often including financial or operational updates, released via a press wire—is characteristic of a general regulatory announcement or a specific type of corporate disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder communication (DEF 14A, PSI), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an announcement *about* a report being published (RPA), but the announcement itself.
2019-12-09 Swedish
Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Regulatory Filings Classification · 95% confidence The document is a press release dated December 5, 2019, announcing that Cantargia AB has selected CAN10 as a development project for systemic sclerosis and myocarditis, originating from their CANxx research platform. It details the scientific rationale, next steps (preclinical studies, goal to initiate Phase I late 2021), and includes standard boilerplate information about the company and the diseases. The text explicitly states, "*This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation.*" This indicates a mandatory regulatory disclosure regarding company operations/pipeline updates, but it is not a formal financial report (like 10-K or IR) or a specific shareholder vote result (DVA). Since it is a general, material announcement required for public disclosure under market regulations, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general regulatory disclosure category is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it discusses R&D pipeline progression, not financial results.
2019-12-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.